Advertisement

Pharmacy

Home Pharmacy
Patients with opioid use disorder undergoing cardiac surgery have increased complications and costs

Complications, Costs Up With Cardiac Sx in Opioid Use Disorder

No increased risk of mortality, but increase in incidence of major complications
For pregnant smokers

Vit C for Pregnant Smokers May Improve Newborn Lung Function

Newborn lung function improved as measured by forced expiratory flow at three months of age
Two drugs have been approved by the U.S. Food and Drug Administration for the treatment of rare blood diseases

FDA Approves Drugs for Treatment of Two Rare Blood Diseases

Elzonris approved to treat BPDCN; Ultomiris approved for paroxysmal nocturnal hemoglobinuria
The risk for atrial fibrillation is increased among antidepressant users

A-Fib Risk Up for Antidepressant Users, but Higher Before Tx

Antidepressant treatment linked to threefold increased risk during first month; link decreased over year
Incorrect prescribing alerts for psychotropic medications may be common

Incorrect Prescribing Alerts Common for Psychotropic Meds

One-third with electronic Rx system that provides alerts believe system provides incorrect warnings
Teething jewelry products

FDA: Teething Jewelry Linked to at Least One Infant Death

Threats from these products include choking, strangulation, injury to the mouth, infection
Patients taking fluoroquinolones may be at higher risk for ruptures or tears in the aorta

FDA: Fluoroquinolones Tied to Heart Vessel Ruptures, Tears

Patients at risk include those with hypertension or certain genetic disorders and the elderly
For patients initiating oral anticoagulant therapy

Hospitalization for Upper GI Bleed Highest With Rivaroxaban

Upper gastrointestinal bleeding hospitalization risk lower for anticoagulant tx with PPI cotherapy
For patients with recurrent or metastatic head and neck squamous cell carcinoma

Pembrolizumab Promising for Metastatic Head, Neck SCC

Prolongs survival among patients with recurrent, metastatic head and neck squamous cell carcinoma
Sorafenib prolongs progression-free survival among patients with desmoid tumors

Sorafenib for Desmoid Tumors Ups Progression-Free Survival

Two-year progression-free survival rate 81 percent with sorafenib vs. 36 percent with placebo